SCHEMBL5145187

SCHEMBL5145187

CC(NS(=O)(=O)c1ccc2ccccc2c1)C(Cc1ccccc1)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 7/20 0.65
CNR2 P34972 7/20 0.65
L3MBTL1 Q9Y468 1/20 0.51
F2 P00734 2/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
CYP19A1 P11511 1/20 0.48
KAT6A Q92794 1/20 0.47
SLC1A3 P43003 1/20 0.46
SLC1A2 P43004 1/20 0.46
SLC1A1 P43005 1/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
TSHR P16473 2/20 0.46
CYP2C19 P33261 2/20 0.46
MAPT P10636 1/20 0.46
PKM P14618 1/20 0.46
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14512579 0.92 CNR1 (0.71) CNR1CNR2L3MBTL1F2KAT6A
SCHEMBL5584580 0.92 CNR1 (0.77) CNR1CNR2
SCHEMBL5145318 0.88 CNR1 (0.75) CNR1CNR2F2
SCHEMBL5180665 0.80 CNR1 (1.00) CNR1CNR2
SCHEMBL14512719 0.80 CNR1 (1.00) CNR1CNR2
SCHEMBL5146661 0.80 CNR1 (0.71) CNR1CNR2
SCHEMBL9942084 0.78 ALDH1A1 (0.60) L3MBTL1MEN1KMT2AKAT6ASLC1A3
SCHEMBL5145061 0.78 CNR1 (0.59) CNR1CNR2L3MBTL1KAT6ACYP1A2
SCHEMBL5145119 0.77 CNR1 (0.76) CNR1CNR2
SCHEMBL5146878 0.77 CNR1 (0.74) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663113-A4 SUBSTITUTED SULFONAMIDES MERCK & CO INC (US) 2007-06-13 EP claimed
US-20070105914-A1 Substituted sulfonamides MERCK SHARP & DOHME CORP. 2007-05-10 US claimed
EP-1663113-A2 SUBSTITUTED SULFONAMIDES Merck & Co., Inc. (US) 2006-06-07 EP claimed
WO-2005027837-A2 SUBSTITUTED SULFONAMIDES MERCK & CO., INC. (US) 2005-03-31 WO claimed
US-20070105914-A1 Substituted sulfonamides MERCK SHARP & DOHME CORP. 2007-05-10 US disclosed
US-20070105914-A1 Substituted sulfonamides MERCK SHARP & DOHME CORP. 2007-05-10 US disclosed
US-20070105914-A1 Substituted sulfonamides MERCK SHARP & DOHME CORP. 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105914-A1 Substituted sulfonamides CNR2, CNR1, FAAH CNR1 2/4885CNR2 1/4885L3MBTL1 3317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.